Werewolf Therapeutics reports 21% ORR for WTX-124 in melanoma, seeks partnerships for INDUKINE programs

Werewolf Therapeutics, Inc.

WTX-124 monotherapy achieved 21% ORR in heavily pretreated advanced melanoma; 30% ORR in patients not primary resistant to prior immunotherapy.
FDA accepted 18 mg as recommended dose for WTX-124; provided guidance for registration path in post-ICI advanced melanoma.
WTX-330 showed one confirmed partial response in metastatic gall bladder cancer with 45% tumor reduction; favorable tolerability.
Company shifting focus to INDUCER T-cell engager platform; IND filings for WTX-1011 (STEAP1) and WTX-2022 (CDH6) planned mid-2027 pending funding.
Additional funding required to initiate further development of both INDUKINE and INDUCER programs; seeking strategic partners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.